Chromadex Corp
NASDAQ:CDXC
Intrinsic Value
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. [ Read More ]
The intrinsic value of one CDXC stock under the Base Case scenario is 1.74 USD. Compared to the current market price of 3.65 USD, Chromadex Corp is Overvalued by 52%.
Valuation Backtest
Chromadex Corp
Run backtest to discover the historical profit from buying and selling CDXC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Chromadex Corp
Current Assets | 49.5m |
Cash & Short-Term Investments | 27.2m |
Receivables | 5.2m |
Other Current Assets | 17.1m |
Non-Current Assets | 5.4m |
PP&E | 4.5m |
Intangibles | 510k |
Other Non-Current Assets | 383k |
Current Liabilities | 20.6m |
Accounts Payable | 10.2m |
Accrued Liabilities | 10.2m |
Other Current Liabilities | 206k |
Non-Current Liabilities | 5.9m |
Long-Term Debt | 12k |
Other Non-Current Liabilities | 5.9m |
Earnings Waterfall
Chromadex Corp
Revenue
|
83.6m
USD
|
Cost of Revenue
|
-32.8m
USD
|
Gross Profit
|
50.8m
USD
|
Operating Expenses
|
-56.4m
USD
|
Operating Income
|
-5.6m
USD
|
Other Expenses
|
661k
USD
|
Net Income
|
-4.9m
USD
|
Free Cash Flow Analysis
Chromadex Corp
What is Free Cash Flow?
CDXC Profitability Score
Profitability Due Diligence
Chromadex Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Chromadex Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
CDXC Solvency Score
Solvency Due Diligence
Chromadex Corp's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Chromadex Corp's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDXC Price Targets Summary
Chromadex Corp
According to Wall Street analysts, the average 1-year price target for CDXC is 5.09 USD with a low forecast of 2.32 USD and a high forecast of 7.35 USD.
Ownership
CDXC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CDXC Price
Chromadex Corp
Average Annual Return | -14.69% |
Standard Deviation of Annual Returns | 30.63% |
Max Drawdown | -94% |
Market Capitalization | 273.7m USD |
Shares Outstanding | 75 309 104 |
Percentage of Shares Shorted | 2.19% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 115 full-time employees. The company went IPO on 2007-06-25. NAD+ is a coenzyme and a regulator of cellular metabolism. The company operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.
Contact
IPO
Employees
Officers
The intrinsic value of one CDXC stock under the Base Case scenario is 1.74 USD.
Compared to the current market price of 3.65 USD, Chromadex Corp is Overvalued by 52%.